Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
196 hedge funds and large institutions have $4.57B invested in Avidity Biosciences in 2024 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 74 increasing their positions, 49 reducing their positions, and 18 closing their positions.
222% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 18
101% more capital invested
Capital invested by funds: $2.28B → $4.57B (+$2.29B)
51% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 49
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
24% more funds holding
Funds holding: 158 → 196 (+38)
5.07% more ownership
Funds ownership: 112.02% → 117.09% (+5.1%)
32% less call options, than puts
Call options by funds: $7.63M | Put options by funds: $11.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$100M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$73.8M |
| 3 |
BlackRock
New York
|
+$70.5M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$69.3M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$60.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$17.2M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$17M |
| 3 |
CAC
Cowen and Company
New York
|
-$14.3M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$12.2M |
| 5 |
JP Morgan Chase
New York
|
-$11.8M |
RNAM Hedge Fund Activity: Q2 2024 in Review
196 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2024, worth a combined $4.57B — up 101% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new RNAM positions and 18 closed out — a net gain of 40 holders — while 74 added to existing stakes and 49 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $100M. The largest seller was Farallon Capital Management, cutting an estimated $17.2M.
- 196 institutional investors held Avidity Biosciences (RNAM) as of Q2 2024, up from 158 in Q1 2024.
- Funds reported $4.57B of Avidity Biosciences stock for Q2 2024, up 101% quarter-over-quarter.
- 58 funds opened new Avidity Biosciences positions in Q2 2024 and 18 closed out, a net change of +40 holders.
- The largest Avidity Biosciences buyer in Q2 2024 was T. Rowe Price Associates, an estimated $100M added.
- The largest Avidity Biosciences seller in Q2 2024 was Farallon Capital Management, an estimated $17.2M sold.
Based on aggregated 13F filings for Q2 2024.